Withdrawal: Makena

Apr. 2023Pharmacy Updates
On March 7, 2023, Covis Pharma announced that it is withdrawing Makena (hydroxyprogesterone caproate injection; also referred to as 17-OHPC) from the market. This drug is used to reduce the risk of preterm birth in women who are pregnant with one baby and have a history of spontaneous preterm birth. Read more about the Makena withdrawal.

Recent Announcements

UPMC Dental Advantage celebrates 15-years of growth

From pilot program to now serving all product lines
Jan. 2026What's New

ACA Risk Adjustment Claims Submission Announcement

Notice: Submit your claims for ACA members
Jan. 2026Important Notices

Register for the Oral Health in Your Pediatric Office CME - accredited webinar

Please join us for a live, CME-accredited webinar on Wednesday, March 11 from noon to 1 p.m. that will provide an overview of oral health in your pediatric office. Providers with a(n) MD/DO, PA, CRNP, RN, or LPN may also apply for topical fluoride certification after completion of this course.
Jan. 2026Education/Webinars